Industry Newsorgan perfusionmedtechtransmedicsrecurring revenue
TransMedics Drives Organ Transplant Market Expansion
4.2
TransMedics Group Inc. (TMDX) is advancing a bullish commercial thesis published Feb. 3, 2026, that highlights its Organ Care System and shift to a recurring-revenue service model. The company reached profitability in 2024, reported $144 million Q3 revenue and roughly 60% gross margins, and holds about 19% U.S. share in heart, lung, and liver transplants. Analysts expect kidney applications by 2027.
Key Points
- 1Highlights TransMedics' shift to recurring-revenue service model retaining OSS consoles and selling high-margin consumables
- 2Notes FDA approvals for heart, lung, liver; kidney indication targeted for 2027, enabling market expansion
- 3Reports profitability in 2024, $144M Q3 revenue, ~60% gross margins, and roughly 19% U.S. transplant share
Scoring Rationale
Detailed company financials and growth thesis, but limited novelty and low relevance to core AI/ML data science.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
